Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Simple item page

Simple item page

Full item details

creativework.keywords - en
ADCC
COVID-19
RBD
SARS-CoV-2
Spike glycoproteins
antibodies
coronavirus
humoral responses
memory B cells
neutralization.
dc.contributor.author
Anand, Sai Priya
Prévost, Jérémie
Nayrac, Manon
Beaudoin-Bussières, Guillaume
Benlarbi, Mehdi
Gasser, Romain
Brassard, Nathalie
Laumaea, Annemarie
Gong, Shang Yu
Bourassa, Catherine
Brunet-Ratnasingham, Elsa
Medjahed, Halima
Gendron-Lepage, Gabrielle
Goyette, Guillaume
Gokool, Laurie
Morrisseau, Chantal
Bégin, Philippe
Martel-Laferrière, Valérie
Tremblay, Cécile
Richard, Jonathan
Bazin, Renée
Duerr, Ralf
Kaufmann, Daniel E.
Finzi, Andrés
dc.date.accessioned
2024-02-23T20:44:22Z
dc.date.available
2024-02-23T20:44:22Z
dc.date.issued
2021-06-15
dc.description.abstract - en
With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines, functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently under investigation as antibody levels in plasma were shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we evaluate the presence of SARS-CoV-2-specific memory B cells in convalescent individuals. Here, we report a longitudinal assessment of humoral immune responses on 32 donors up to 8 months post-symptom onset. Our observations indicate that anti-Spike and anti-receptor binding domain (RBD) immunoglobulin M (IgM) in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity also declines rapidly when compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which remain stable. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for secondary infection prevention and vaccine efficacy.
dc.identifier.citation
Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, Brassard N, Laumaea A, Gong SY, Bourassa C, Brunet-Ratnasingham E, Medjahed H, Gendron-Lepage G, Goyette G, Gokool L, Morrisseau C, Bégin P, Martel-Laferrière V, Tremblay C, Richard J, Bazin R, Duerr R, Kaufmann DE, Finzi A. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Rep Med. 2021 Jun 15;2(6):100290. doi: 10.1016/j.xcrm.2021.100290. Epub 2021 May 5.
dc.identifier.doi
https://doi.org/10.1016/j.xcrm.2021.100290
dc.identifier.issn
2666-3791
dc.identifier.pubmedID
33969322
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/1969
dc.language.iso
en
dc.publisher
Cell Press
dc.rights - en
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr
Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.uri - en
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en
Health
dc.subject - fr
Santé
dc.subject.en - en
Health
dc.subject.fr - fr
Santé
dc.title - en
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
dc.type - en
Article
dc.type - fr
Article
local.article.journalissue
6
local.article.journaltitle
Cell Reports Medicine
local.article.journalvolume
2
local.peerreview - en
Yes
local.peerreview - fr
Oui
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: anand-longitudinal-humoral-immunity-sars-cov2-post-symptom.pdf

Size: 3.93 MB

Format: PDF

Download file

Page details

Date modified: